Literature DB >> 31635805

α-Synuclein chaperone suppresses nucleation and amyloidogenesis of prion protein.

Maki Shirasaka1, Kazuo Kuwata2, Ryo Honda3.   

Abstract

Protein misfolding diseases are a group of devastating disorders characterized by structural conversion of a soluble protein into an amyloid-like aggregate. Typically, the structural conversion occurs by misfolding of a single disease-associated protein, such as α-synuclein (αS) in Parkinson's disease, amyloid-β in Alzheimer's disease, and prion protein (PrP) in transmissible spongiform encephalopathies (TSEs). However, accumulating evidence has implicated that cross-interactions between heterologous amyloidogenic proteins dramatically impact on amyloidogenesis and disease pathology. Here we show αS in a monomeric state can suppress amyloidogenesis of PrP in vitro. Thioflavin-T assays and transmission electron miscopy revealed that monomeric αS inhibits the nucleation step of amyloidogenesis without inhibiting the growing step. Surface plasmon resonance and co-sedimentation assays neither detected interaction between αS and monomeric PrP nor fibrillar PrP. These results suggested that αS suppress amyloidogenesis of PrP by binding to a transiently accumulated intermediate, such as a partially unfolded state. Moreover, we found that oligomeric αS, which was recently suggested to interact with PrP, also did not interact with PrP. Taken together, our study revealed a chaperon-like activity of αS against PrP amyloidogenesis, suggesting a possible involvement of αS in the pathology of TSEs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31635805     DOI: 10.1016/j.bbrc.2019.10.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts.

Authors:  Izabella Grimaldi; Felipe Saceanu Leser; José Marcos Janeiro; Bárbara Gomes da Rosa; Ana Clara Campanelli; Luciana Romão; Flavia Regina Souza Lima
Journal:  J Mol Med (Berl)       Date:  2022-09-03       Impact factor: 5.606

2.  Monomeric a-synuclein (aS) inhibits amyloidogenesis of human prion protein (hPrP) by forming a stable aS-hPrP hetero-dimer.

Authors:  Satoshi Yamashita; Yuji O Kamatari; Ryo Honda; Ayumi Niwa; Hiroyuki Tomiata; Akira Hara; Kazuo Kuwata
Journal:  Prion       Date:  2021-12       Impact factor: 3.931

3.  Kaempferol Has Potent Protective and Antifibrillogenic Effects for α-Synuclein Neurotoxicity In Vitro.

Authors:  Masatoshi Inden; Ayaka Takagi; Hazuki Kitai; Taisei Ito; Hisaka Kurita; Ryo Honda; Yuji O Kamatari; Sora Nozaki; Xiaopeng Wen; Masanori Hijioka; Yoshihisa Kitamura; Isao Hozumi
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

4.  Spatiotemporal modulations in heterotypic condensates of prion and α-synuclein control phase transitions and amyloid conversion.

Authors:  Aishwarya Agarwal; Lisha Arora; Sandeep K Rai; Anamika Avni; Samrat Mukhopadhyay
Journal:  Nat Commun       Date:  2022-03-03       Impact factor: 14.919

5.  Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability.

Authors:  Makoto Hashimoto; Gilbert Ho; Yoshiki Takamatsu; Ryoko Wada; Shuei Sugama; Masaaki Waragai; Eliezer Masliah; Takato Takenouchi
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.